07:40 AM EDT, 10/14/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Monday that data from a phase 3 study showed that more patients with moderately to severely active Crohn's disease achieved histologic response with mirikizumab treatment at week 52 compared with ustekinumab.

The company said mirikizumab achieved statistically significant improvements across all histologic and histologic-endoscopic endpoints compared with placebo at weeks 12 and 52. Mirikizumab's safety profile was consistent with the known safety profile in patients with ulcerative colitis, Eli Lilly ( LLY ) added.

Mirikizumab is approved for the treatment of moderately to severely active ulcerative colitis and has pending marketing authorization applications in Crohn's disease globally, Eli Lilly ( LLY ) said.

Price: 933.04, Change: +0.98, Percent Change: +0.11